SCHEMBL7123694

SCHEMBL7123694

Cc1cccc(NC=O)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
TSHR P16473 2/20 0.38
PABPC1 P11940 1/20 0.37
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
ALDH1A1 P00352 4/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 2/20 0.34
GPR35 Q9HC97 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MEN1 O00255 1/20 0.34
AKR1B10 O60218 1/20 0.34
ABCB11 O95342 1/20 0.34
TTR P02766 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34
FABP2 P12104 1/20 0.34
RXRA P19793 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115093 0.82 KDM5A (0.34) LMNATSHRPABPC1ALDH1A1MEN1
SCHEMBL448938 0.79 MEN1 (0.50) LMNATSHRPABPC1ALDH1A1NPC1
SCHEMBL4776892 0.79 KEAP1 (0.52) LMNATSHRKEAP1NFE2L2ALDH1A1
SCHEMBL225741 0.79 NPC1 (0.50) TSHRPABPC1ALDH1A1NPC1RAB9A
SCHEMBL9800976 0.79 NPC1 (0.50) TSHRPABPC1ALDH1A1NPC1RAB9A
SCHEMBL9840547 0.78 TSHR (0.39) TSHRPABPC1KEAP1NFE2L2ALDH1A1
SCHEMBL11409022 0.77 NPC1 (0.48) TSHRPABPC1ALDH1A1NPC1RAB9A
SCHEMBL5514299 0.76 TSHR (0.44) LMNATSHRPABPC1KEAP1NFE2L2
SCHEMBL9685869 0.76 TSHR (0.38) LMNATSHRPABPC1KEAP1NFE2L2
SCHEMBL13412750 0.76 ALDH1A1 (0.50) LMNATSHRPABPC1KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207865-A1 Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents DIXON BRIAN R (US) 2003-11-06 US disclosed
US-6353006-B1 TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT BAYER CORPORATION 2002-03-05 US disclosed
EP-1144396-A2 SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS Bayer Corporation (US) 2001-10-17 EP disclosed
WO-2000042031-A2 SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS BAYER CORPORATION (US) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207865-A1 Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents PGR, PGRMC2, PGRMC1 LMNA 3221/4885TSHR 67/4885PABPC1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.